

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known					
				Application Number	10/603,094
				Filing Date	June 25, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1045 1648
Examiner Name				To Be Assigned Louise Humphrey	
Sheet	1	of	8	Attorney Docket Number	1954-410

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
LH	A.	6,156,317		Diamond et al.	12-05-2000
LH	B.	6,074,645		Diamond et al.	06-13-2000


FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
LH	C.	WO	00/75180	A2	Florian Kern	12-14-2000	
	D.	WO	94/00150	A1	City of Hope	01-06-1994	
	E.	WO	97/40165	A1	The Wistar Institute of Anatomy and Biology	10-30-1997	
	F.	WO	98/26074	A1	Institut National De La Sante et de La Recherche Medicale	06-18-1998	
↓	G.	WO	99/19349	A1	City of Hope	04-22-1999	

Examiner Signature	/Louise Humphrey/ (09/13/2006)	Date Considered	
--------------------	--------------------------------	-----------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 				Complete if Known	
				Application Number	10/603,094
				Filing Date	June 25, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645 1648
				Examiner Name	To Be Assigned
Sheet	2	of	8	Attorney Docket Number	1954-410
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
LH	H.	Alexander, Jeff, et al., "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," <u>Immunity</u> 1:751-761, December 1994.			
	I.	Alexander, Jeff, et al., "Derivation of HLA-A11/K ^b Transgenic Mice: Functional CTL Repertoire and Recognition of Human A11-Restricted Epitopes," <u>The Journal of Immunology</u> 159:4753-4761, 1997.			
	J.	Altman, John D., et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," <u>Science</u> 274:94-96, October 4, 1996.			
	K.	Appay, Victor, et al., "HIV-specific CD8 ⁺ T Cells Produce Antiviral Cytokines but are Impaired in Cytolytic Function," <u>J. Exp. Med.</u> 192(1):63-75, July 3, 2000.			
	L.	Banchereau, Jacques, et al., "Immune and Clinical Responses in Patients with Metastatic Melanoma to CD34 ⁺ Progenitor-derived Dendritic Cell Vaccine," <u>Cancer Research</u> 61:6451-6458, September 1, 2001.			
	M.	Belyakov, Igor M., et al., "Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques," <u>Nature Medicine</u> 7(12):1320-1326, December 2001.			
	N.	BenMohamed L., et al., "Induction of CTL Response by a Minimal Epitope Vaccine in HLA A*0201/DR1 Transgenic Mice: Dependence on HLA Class II Restricted T _H Response," <u>Human Immunology</u> , 61:764-779, 2000.			
	O.	BenMohamed, Lbachir, et al., "Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses," <u>Immunology</u> 106:113-121, 2002.			
	P.	Berger, Carolina, et al., "Nonmyeloablative Immunosuppressive Regimen Prolongs In Vivo Persistence of Gene-Modified Autologous T Cells in a Nonhuman Primate Model," <u>Journal of Virology</u> 75(2):799-808, January 2001.			
	Q.	Bernhard, Eric et al., "Cytotoxic T Lymphocytes from HLA-A2 Transgenic Mice Specific for HLA-A2 Expressed on Human Cells," <u>J. Exp. Med.</u> 168:1157-1162, September 1988.			
	R.	Borysiewicz, Leszek, et al., "Human Cytomegalovirus-Specific Cytotoxic T Lymphocytes: Requirements for <i>in Vitro</i> Generation and Specificity," <u>Eur. J. Immunol.</u> 13:804-809, 1983.			
↓	S.	Boyer, Jean D., et al., "Vaccination of Seronegative Volunteers with a Human Immunodeficiency Virus Type 1 <i>env</i> rev DNA Vaccine Induces Antigen-Specific Proliferation and Lymphocyte Production of β -Chemokines," <u>The Journal of Infectious Diseases</u> 181:476-83, 2000.			
Examiner Signature	/Louise Humphrey/ (09/13/2006)			Date Considered	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 				<i>Complete if Known</i>	
				Application Number	10/603,094
				Filing Date	June 25, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	3	of	8	Attorney Docket Number	1954-410
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
LH	T.	Chu, Rose S., et al., "CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity," <u>J. Exp. Med.</u> 186(10):1623-1631, November 17, 1997.			
	U.	Cwynarski, Kate, et al., "Direct Visualization of Cytomegalovirus-Specific T-Cell Reconstitution after Allogeneic Stem Cell Transplantation," <u>Blood</u> 97(5):1232-1240, March 1, 2001.			
	V.	Davis, Heather L., et al., "CpG DNA Is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen," <u>The Journal of Immunology</u> 160:870-876, 1998.			
	W.	Del Val, Margarita, et al., "Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein," <u>Cell</u> 68:1145-1153, September 20, 1991.			
	X.	Del Val, Margarita, et al., "Protection Against Lethal Cytomegalovirus Infection by a Recombinant Vaccine Containing a Single Nonameric T-Cell Epitope," <u>Journal of Virology</u> 65(7):3641-3646, July 1991.			
	Y.	Deres, Karl, et al., "In vivo priming of a virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccines," <u>Nature</u> 342:561-564, November 30, 1989.			
	Z.	Diamond, Don J., et al., "Development of a Candidate HLA A*0201 Restricted Peptide Based Vaccine Against HCMV Infection," <u>Blood</u> 90(5):1751-1767, September 1, 1997.			
	AA.	Einsele, Hermann, et al., "Infusion of Cytomegalovirus (CMV)-Specific T Cells for the Treatment of CMV Infection Not Responding to Antiviral Chemotherapy," <u>Blood</u> 99(11):3916-3922, June 1, 2002.			
	BB.	Freitag, L.C., et al., "Bacterial Toxins as Mucosal Adjuvants," <u>Curr. Top. Microbiol. Immunol.</u> 236:215-236, 1999.			
	CC.	Gahéry-Ségard, Hanne, et al., "Multiepitopic B- and T-Cell Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine," <u>Journal of Virology</u> 74(4):1694-1703, February 2000.			
	DD.	Gratama, Jan. W., et al., "Tetramer-based Quantification of Cytomegalovirus (CMV)-Specific CD8 ⁺ T Lymphocytes in T-Cell-Depleted Stem Grafts and after Transplantation May Identify Patients at Risk for Progressive CMV Infection," <u>Blood</u> 98(5):1358-1364, September 1, 2001.			
	EE.	Grefte, J.M., et al., "The Lower Matrix Protein pp65 is the Principal Viral Antigen Present in Peripheral Blood Leukocytes During an Active Cytomegalovirus Infection," <u>Journal of General Virology</u> 73:2923-2932, 1992.			
↓	FF.	Gyulai, Zsolia, et al., "Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1-Specific CTLs," <u>The J. of Infectious Diseases</u> 181:1537-46, 2000.			
Examiner Signature		/Louise Humphrey/ (09/13/2006)		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 				<i>Complete if Known</i>	
				Application Number	10/603,094
				Filing Date	June 25, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	4	of	8	Attorney Docket Number	1954-410
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
LH	GG.	Hart, Mary Kate, et al., "Priming of Anti-Human Immunodeficiency Virus (HIV) CD8 ⁺ Cytotoxic T Cells <i>in Vivo</i> by Carrier-Free HIV Synthetic Peptides," <u>Proc. Natl. Acad. Sci USA</u> 88:9448-9452, November 1991.			
	HH.	Heathcote, Jenny, et al., "A Pilot Study of the CY-1899 T-Cell Vaccine in Subjects Chronically Infected with Hepatitis B Virus," <u>Hepatology</u> 30(2):531-536, August 1999.			
	II.	Hernández, Javier, et al., "The Use of HLA A2.1/p53 Peptide Tetramers to Visualize the Impact of Self Tolerance on the TCR Repertoire," <u>The Journal of Immunology</u> 164:596-602, 2000.			
	JJ.	Hioe, Catarina, et al., "Comparison of Adjuvant Formulations for Cytotoxic T Cell Induction Using Synthetic Peptides," <u>Vaccine</u> 14(5):412-418, 1996.			
	KK.	Horner, Anthony A., et al., "Immunostimulatory DNA-Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic and Mucosal Sites," <u>The Journal of Immunology</u> 167:1584-1591, 2001.			
	LL.	Ishioka, Glenn Y., et al. "Utilization of MHC Class I Transgenic Mice for Development of Minigen DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes," <u>J. Immunology</u> 162:3915-3925, 1999.			
	MM.	Kern, Florian, et al., "Analysis of CD8 T Cell Reactivity to Cytomegalovirus Using Protein-Spanning Pools of Overlapping Pentadecapeptides," <u>Eur. J. Immunol.</u> 30:1676-1682, 2000.			
	NN.	Kern, Florian, et al., "Target Structures of the CD8 ⁺ -T-Cell Response to Human Cytomegalovirus: the 72 Kilodalton Major Immediate-Early Protein Revisited," <u>J. of Virology</u> 73(10):8179-8184, October 1999.			
	OO.	Klinman, D.M., et al., "CpG DNA Augments the Immunogenicity of Plasmid DNA Vaccines," <u>Curr. Top. Microbiol. Immunol.</u> 247:131-142, 2000.			
	PP.	Krieg, Arthur M., et al., "CpG Motifs in Bacterial DNA and Their Immune Effects," <u>Annu. Rev. Immunol.</u> 20:709-760, 2002.			
	QQ.	Krieg, Arthur M., et al., "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," <u>Nature</u> 374(6):546-549, April 6, 1995.			
▼	RR.	Krieg, Arthur M., et al., "Enhancing Vaccines with Immune Stimulatory CpG DNA," <u>Current Opinion in Molecular Therapeutics</u> 3(1):15-24, 2001.			
Examiner Signature		/Louise Humphrey/ (09/13/2006)		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/603,094
				Filing Date	June 25, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	5	of	8	Attorney Docket Number	1954-410
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
LH	SS.	Krieg, Arthur M., et al., "Sequence Motifs in Adenoviral DNA Block Immune Activation by Stimulatory CpG Motifs," <u>Proc. Natl. Acad. Sci. USA</u> 95:12631-12636, October 1998.			
	TT.	La Rosa, Corinna, et al., "Enhanced Immune Activity of Cytotoxic T-Lymphocyte Epitope Analogs Derived from Positional Scanning Synthetic Combinatorial Libraries," <u>Blood</u> 97(6):1776-1786, March 15, 2001.			
	UU.	Li, Cheng-Rong, et al., "Recovery of HLA-Restricted Cytomegalovirus (CMV)-Specific T-Cell Responses After Allogeneic Bone Marrow Transplant: Correlation with CMV Disease and Effect of Ganciclovir Prophylaxis," <u>Blood</u> 83(7):1971-1979, 1994.			
	VV.	Limaye, Ajit P., et al., "High Incidence of Ganciclovir-Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy," <u>The Journal of Infectious Diseases</u> 185:20-7, 2002.			
	WW.	Lipford, G.B., et al. "Peptide Engineering Allows Cytotoxic T-cell Vaccination Against Human Papilloma Virus Tumour Antigen, E6," <u>Immunology</u> 84:298-303, 1995.			
	XX.	Lipford, Grayson B., et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants," <u>Eur. J. Immunol.</u> 27:2340-2344, 1997.			
	YY.	Livingston, Brian D., et al. "Altered Helper T Lymphocyte Function Associated with Chronic Hepatitis B Virus Infection and its Role in Response to Therapeutic Vaccination in Humans," <u>J. Immunology</u> 162:3088-3095, 1999.			
	ZZ.	Livingston, Brian D., et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>The Journal of Immunology</u> , 159:1383-1392, 1997.			
	AAA.	Longmate, Jeffrey, et al., "Population Coverage by HLA Class-I Restricted Cytotoxic T-Lymphocyte Epitopes," <u>Immunogenetics</u> 52:165-173, 2001.			
	BBB.	Ludewig, Burkhard, et al., "Dendritic Cells Efficiently Induce Protective Antiviral Immunity," <u>Journal of Virology</u> 72(5):3812-3818, May 1998.			
	CCC.	Martinon, Frederic, et al., "Immunization of Mice with Lipopeptides Bypasses the Prerequisite for Adjuvant: Immune Response of BALB/c Mice to Human Immunodeficiency Virus Envelope Glycoprotein," <u>The Journal of Immunology</u> 149(10):3416-3422, November 15, 1992.			
▼	DDD.	McCluskie, Michael J., et al., "Mucosal Immunization of Mice Using CpG DNA and/or Mutants of the Heat-Labile Enterotoxin of <i>Escherichia coli</i> as Adjuvants," <u>Vaccine</u> 19:3759-3768, 2001.			
Examiner Signature	/Louise Humphrey/ (09/13/2006)			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/603,094
				Filing Date	June 25, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	6	of	8	Attorney Docket Number	1954-410
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
LH	EEE.	McLaughlin-Taylor, Elizabeth, et al., "Identification of the Major Late Human Cytomegalovirus Matrix Protein pp65 as a Target Antigen for CD8 ⁺ Virus-Specific Cytotoxic T Lymphocytes," <u>Journal of Medical Virology</u> 43:103-110, 1994.			
	FFF.	Millan, Cynthia L. Brazolot, et al., "CpG DNA Can Induce Strong Th1 Humoral and Cell-mediated Immune Response against Hepatitis B Surface Antigen in Young Mice," <u>Proc. Natl. Acad. Sci. USA</u> 95:15553-15558, December 1998.			
	GGG.	Moldoveanu, Zina, et al., "CpG DNA, a Novel Immune Enhancer for Systemic and Mucosal Immunization with Influenza Virus," <u>Vaccine</u> , 16(11/12):1216-1224, 1998			
	HHH.	Mora, Ana L., et al., "Controlled Lipidation and Encapsulation of Peptides as a Useful Approach to Mucosal Immunization," <u>The Journal of Immunology</u> 161:3616-3623, 1998.			
	III.	Morris, Cindy B, et al., "Effectiveness of Intranasal Immunization with HIV-gp160 and an HIV-1 Env CTL Epitope Peptide (E7) in Combination with the Mucosal Adjuvant LT (R192G)," <u>Vaccine</u> 18:1944-1951, 2000.			
	JJJ.	Newman, M.J., et al., "Induction of Cross-reactive Cytotoxic T-lymphocyte Responses Specific for HIV-1 gp120 Using Saponin Adjuvant (QS-21) Supplemented Subunit Vaccine Formulations," <u>Vaccine</u> 15(9):1001-1007, 1997.			
	KKK.	Nichols, W. Garrett, et al., "High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)-Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effect of Primary CMV Infection," <u>The Journal of Infectious Diseases</u> 185:273-82, 2002.			
	LLL.	Pande, Hema, et al., "Human Cytomegalovirus Strain Towne pp65 Gene: Nucleotide Sequence and Expression in <i>Escherichia coli</i> ," <u>Virology</u> 182: 220-228, 1991.			
	MMM.	Partidos, C.D., et al., "CTL Responses Induced by a Single Immunization with Peptide Encapsulated in Biodegradable Microparticles," <u>Journal of Immunological Methods</u> 206:143-151, 1997.			
	NNN.	Parker, Kenneth C., et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <u>Journal of Immunology</u> , 152:163-175, 1994.			
	OOO.	Rammensee, Hans-Georg, et al., "MHC Ligands and Peptide Motifs: First Listing," <u>Immunogenetics</u> , 41(4):178-228, 1995.			
V	PPP.	Rammensee, Hans-Georg, et al., "Peptides Naturally Presented by MHC Class I Molecules," <u>Annu. Rev. Immunol.</u> 11:213-44, 1993.			
Examiner Signature	/Louise Humphrey/ (09/13/2006)			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/603,094
				Filing Date	June 25, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	7	of	8	Attorney Docket Number	1954-410
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
LH	QQQ.	Rasmussen, L., "Immune Response to Human Cytomegalovirus Infection," <u>Current Topics in Microbiology and Immunology</u> 154:222-254 (1990).			
	RRR.	Reece, Jeannette, et al., "Mapping the Major Human T Helper Epitopes of Tetanus Toxin: the Emerging Picture," <u>J. Immunol.</u> 151(11):6175-6184, December 1, 1993.			
	SSS.	Retière, Christelle, et al., "Generation of Cytomegalovirus-Specific Human T-Lymphocyte Clones by Using Autologous B-Lymphoblastoid Cells with Stable Expression of pp65 or IE1 Proteins: a Tool to Study the Fine Specificity of the Antiviral Response," <u>J. of Virology</u> 74(9):3948-3952, May 2000.			
	TTT.	Riddell, Stanley, et al., "Class I MHC-Restricted Cytotoxic T Lymphocyte Recognition of Cells Infected with Human Cytomegalovirus does not Require Endogenous Viral Gene Expression," <u>J. Immunology</u> 146(8):2795-2804, April 15, 1991.			
	UUU.	Riddell, Stanley, et al., "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones," <u>Science</u> 257:238-241, 1992.			
	VVV.	Rock, Kenneth, et al., "Degradation of Cell Proteins and the Generation of MHC Class 1-Presented Peptides," <u>Annu. Rev. Immunol.</u> 17:739-779, 1999.			
	WWW	Rosloniec, Edward, et al., "An HLA-DR1 Transgene Confers Susceptibility to Collagen-induced Arthritis Elicited with Human Type II Collagen," <u>J. Exp. Med.</u> 185(6):1113- 1122, March 17, 1997.			
	XXX.	Sauzet, Jean-Pierre, et al., "Long-lasting anti-viral Cytotoxic T Lymphocytes Induced <i>In Vivo</i> with Chimeric-multirestricted Lipopeptides," <u>Vaccine</u> 13(14):1339-1345, 1995.			
	YYY.	Schild, Hansjörg, et al., "Efficiency of peptides and lipopeptides for <i>in vivo</i> priming of virus-specific cytotoxic T cells," <u>Eur. J. Immunol.</u> 21:2649-2654, 1991.			
	ZZZ.	Schulz, Manfred., et al., "Peptide-induced Antiviral Protection by Cytotoxic T Cells," <u>Proc. Natl. Acad. Sci. USA</u> 88:991-993, February 1991.			
	AAAA.	Seth, Aruna, et al., "Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-seropositive Individuals," <u>AIDS Res. Hum. Retroviruses</u> 16(4):337-343, 2000.			
	BBBB.	Shirai, Mutsunori, et al., "Helper-cytotoxic T Lymphocyte (CTL) Determinant Linkage Required for Priming of Anti-HIV CD8 ⁺ CTL <i>in vivo</i> with Peptide Vaccine Constructs," <u>J. Immunol.</u> 152:549-556, 1994.			
	CCCC.	Stratton, Kathleen R., et al., <u>Vaccines for the 21st Century: A tool for Decisionmaking</u> . Bethesda, National Academy Press, 2001, pp. ix-xi.			
↓	DDDD.	Tighe, Helen, et al., "Conjugation of Protein to Immunostimulatory DNA Results in a Rapid, Long-lasting and Potent Induction of Cell-mediated and Humoral immunity," <u>Eur. J. Immunol.</u> 30:1939-1947, 2000.			
Examiner Signature		/Louise Humphrey/ (09/13/2006)		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/603,094
				Filing Date	June 25, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	8	of	8	Attorney Docket Number	1954-410
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
LH	EEEE.	Tobery, Timothy et al., "Cutting Edge: Induction of Enhanced CTL-Dependent Protective Immunity in Vivo by N-End Rule Targeting of a Model Tumor Antigen," <u>The Journal of Immunology</u> 162:639-642, 1999.			
	FFFF.	Tobery and Siliciano, "Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses in vivo After Immunization," <u>J. Exp. Med.</u> 185(5):909-920, 1997.			
	GGGG.	Tsunoda, Ikuo, et al. "Lipopeptide Particles as the Immunologically Active Component of CTL Inducing Vaccines," <u>Vaccine</u> 17:675-685, 1999.			
	HHHH.	Ureta-Vidal, Abel, et al., "Phenotypical and Functional Characterization of the CD8 ⁺ T Cell Repertoire of HLA-A2.1 Transgenic, H-2KbnullDbnull Double Knockout Mice," <u>J. Immunol.</u> 163:2555-2560, 1999.			
	IIII.	Varshavsky, Alexander, "The N-end Rule: Functions, Mysteries, Uses," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 93:12142-12149, 1996.			
	JJJJ.	Villacres, Maria C., et al., "Human Immunodeficiency Virus-infected Patients Receiving Highly Active Antiretroviral Therapy Maintain Activated CD8 ⁺ T Cell Subsets as a Strong Adaptive Immune Response to Cytomegalovirus," <u>J. Infect. Dis.</u> 184:256-267, 2001.			
	KKKK.	Vitiello, Antonella, et al., "Comparison of Cytotoxic T Lymphocyte Responses Induced by Peptide or DNA Immunization: Implications on Immunogenicity and Immunodominance," <u>Eur. J. Immunol.</u> 27:671-678, 1997.			
	LLLL.	Walter, Elizabeth, et al., "Reconstitution of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor," <u>The New England Journal of Medicine</u> 333(16):1038-1044, October 19, 1995.			
	MMMM.	Wentworth, Peggy, et al. "In Vitro induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," <u>Molecular Immunology</u> 32(9):603-612, 1995.			
	NNNN.	Wei, Maria L., et al., "HLA-A2 Molecules in an Antigen-processing Mutant Cell Contain Signal Sequence-derived Peptides," <u>Nature</u> 356:443-446, April 12, 1992.			
	OOOO.	Wiedemann, Frank et al., "Histopathological Studies on the Local Reactions Induced by Complete Freund's Adjuvant (CFA), Bacterial Lipopolysaccharide (LPS), and Synthetic Lipopeptide (P3C) Conjugates," <u>J. Pathol.</u> 164:265-271, 1991.			
	PPPP.	Wills, Mark R., et al., "The Human Cytotoxic T-Lymphocyte (CTL) Response to Cytomegalovirus is Dominated by Structural Protein pp65: Frequency, Specificity, and T-Cell Receptor Usage of pp65-Specific CTL," <u>J. of Virol.</u> 70(11):7569-7579, Nov. 1996.			
✓	QQQQ.	Zaia, John A., et al., "Status of Cytomegalovirus Prevention and Treatment in 2000," <u>Hematology</u> , pp. 339-355, 2000.			
Examiner Signature	/Louise Humphrey/ (09/13/2006)			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	10/603,094
Filing Date	June 25, 2003
First Named Inventor	Don J. DIAMOND
Group Art Unit	1648
Examiner Name	Laurie Scheiner Louise Humphrey
Attorney Docket Number	1954-410

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
LH	1.	6,544,521	B2	Diamond	04-08-2003
LH	2.	6,562,345	B1	Diamond	05-13-2003

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			

Examiner
Signature


/Louise Humphrey/ (09/13/2006)

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



Complete if Known

Application Number	10/603,094
Filing Date	June 25, 2003
First Named Inventor	Don J. DIAMOND
Group Art Unit	4645 1648
Examiner Name	To Be Assigned Louise Humphrey

Sheet	1	of	3	Attorney Docket Number	1954-410
-------	---	----	---	------------------------	----------

U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
LH	1A	U.S. 5,736,142		SETTE et al.	04/07/1998
LH	1B	U.S. 6,472,375	B1	HOON et al.	10/29/2002
LH	1C	U.S. 6,514,948	B1	RAZ et al.	02/04/2003
LH	1D	U.S. 6,632,435	B1	DIAMOND	10/14/2003

Examiner Signature	/Louise Humphrey/ (09/13/2006)	Date Considered	
-----------------------	--------------------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.


⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 			<i>Complete if Known</i>		
			Application Number	10/603,094	
			Filing Date	June 25, 2003	
			First Named Inventor	Don J. DIAMOND	
			Group Art Unit	1645	
			Examiner Name	To Be Assigned	
Sheet	2	3	Attorney Docket Number		1954-410
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
LH	1E	AHLERS et al., "High-Affinity T Helper Epitope Induces Complementary Helper and APC Polarization, Increased CTL, and Protection Against Viral Infection," J. Clin. Invest., 108(11)1677-85, 2001.			
LH	1F	ALEXANDER et al., "A Decapeptide Polypeptide Primes for Multiple CD8+ INF-γ and Th Lymphocyte Responses: Evaluation of Multiepitope Polypeptides as a Mode for Vaccine Delivery," J. Immunol., 168:6189-6198, 2002.			
LH	1G	CAFARO et al., "Vaccination with DNA Containing tat Coding Sequences and Unmethylated CpG Motifs Protects Cynomolgus Monkeys Upon Infection with Simian/Human Immunodeficiency Virus (SHIV89.6P)," Vaccine, 19:2862-2877, 2001.			
LH	1H	CHEE et al., "Analysis of the Protein-Coding Content of the Sequence of Human cytomegalovirus Strain AD169," Curr. Topics Microbiol. Immunol., 154:126-169, 1990.			
LH	1I	CHO et al., "Immunostimulatory DNA-based Vaccines Induce Cytotoxic Lymphocyte Activity by a T-Helper Cell-Independent Mechanism," Nat. Biotechnol., 18:509-514, 2000.			
LH	1J	CHO et al., "IFN-αβ Promote Priming of Antigen-Specific CD8+ and CD4+ T Lymphocytes by Immunostimulatory DNA-Based Vaccines," J. Immunol., 168:4907-4913, 2002.			
LH	1K	ELIAS et al., "Strong Cytosine-Guanosine-Independent Immunostimulation in Humans and other Primates by Synthetic Oligodeoxynucleotides with PyNTTTTGT Motifs," J. Immunol., 171:3697-3704, 2003.			
LH	1L	GÜRSEL et al., "Differential and Competitive Activation of Human Immune Cells by Distinct Classes of CpG Oligodeoxynucleotide," J. Leukocyte. Biol., 71:813-820, 2002.			
LH	1M	HO et al., "An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems," J. Immunol., 171:4920-4926, 2003.			
LH	1N	KHATTAB et al., "Three T-Cell Epitopes Within the C-Terminal 265 Amino Acids of the Matrix Protein pp65 of Human Cytomegalovirus Recognized by Human Lymphocytes," J. Med. Virol., 52:68-76, 1997.			
LH	1O	KLINMAN et al., "CpG DNA: Recognition by and Activation of Monocytes," Microbes Infection 4:897-901, 2002.			
LH	1P	KRUG et al., "Identification of CpG Oligonucleotide Sequences with High Induction of IFN-α/β in Plasmacytoid Dendritic Cells," Eur. J. Immunol., 31:2154-2163, 2001.			
Examiner Signature		/Louise Humphrey/ (09/13/2006)		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



Complete if Known

Application Number	10/603,094
Filing Date	June 25, 2003
First Named Inventor	Don J. DIAMOND
Group Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	1954-410

Sheet 3 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LH	1Q	MESEDA et al., "Prime-Boost Immunization with DNA and Modified Vaccinia Virus Ankara Vectors Expressing Herpes Simplex Virus-2 Glycoprotein D Elicits Greater Specific Antibody and Cytokine Responses than DNA Vaccine Alone," J. Infect. Dis., 186:1065-73, 2002.	
	1R	NIJMAN et al., "Identification of Peptide Sequences That Potentially Trigger HLA-A2.1-Restricted Cytotoxic T Lymphocytes," Eur. J. Immunol., 23:1215-1219, 1993.	
	1S	OSEROFF et al., "Pools of Lipidated HTL-CTL Constructs Prime For Multiple HBV and HCV CTL Epitope Responses," Vaccine, 16(8):823-833, 1998.	
	1T	RUGER et al., "Primary Structure and Transcription of the Genes Coding for the Two Virion Phosphoproteins pp65 and pp71 of Human Cytomegalovirus," J. Virol., 61(2):446-453, 1987.	
	1U	SANO et al., "Oligodeoxynucleotides Without CpG Motifs Work as Adjuvant for the Induction of Th2 Differentiation in a Sequence-Independent Manner," J. Immunol., 170:2367-2373, 2003.	
	1V	SCHIRMBECK et al., "Antigenic Epitopes Fused to Cationic Peptide Bound to Oligonucleotides Facilitate Toll-Like Receptor 9-Dependent, but CD4+ T Cell Help-Independent, Priming of CD8+ T Cells," J. Immunol., 171:5198-5207, 2003.	
	1W	SHIRAI et al., "Helper-Cytotoxic T Lymphocyte (CTL) Determinant Linkage Required for Priming of Anti-HIV CD8+ CTL in Vivo with Peptide Vaccine Constructs," J. Immunol., 152:549-556, 1994.	
	1X	SOLACHE et al., "Identification of Three HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in the Cytomegalovirus Protein pp65 That Are Conserved Between Eight Strains of the Virus," J. Immunol., 163:5512-5518, 1999.	
	1Y	SPAETE et al., "Human Cytomegalovirus Strain Towne Glycoprotein B is Processed by Proteolytic Cleavage," Virology 167:207-225, 1988.	
✓	1Z	VERTHELYI et al., "Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs," J. Immunol., 166:2372-2377, 2001.	

Examiner Signature	/Louise Humphrey/ (09/13/2006)	Date Considered	
--------------------	--------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.